NEXTCURE INC. - COMMO

A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

12 9 2023 08:05:00 提供 Nasdaq GlobeNewswire

NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

07 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

05 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

31 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

03 8 2023 16:05:01 提供 Nasdaq GlobeNewswire

NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

21 6 2023 16:05:00 提供 Nasdaq GlobeNewswire

NextCure to Present at the JMP Securities Life Sciences Conference

09 5 2023 07:00:01 提供 Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

04 5 2023 16:05:02 提供 Nasdaq GlobeNewswire

NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

11 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

NextCure Provides Business Update and Reports Full Year 2022 Financial Results

02 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

NextCure to Present at SVB Securities Global Biopharma Conference

07 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

NextCure to Present at Upcoming Investor Conferences

22 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

15 11 2022 16:30:00 提供 Nasdaq GlobeNewswire

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

07 11 2022 08:05:00 提供 Nasdaq GlobeNewswire

NextCure Provides Update and Reports Third Quarter 2022 Financial Results

03 11 2022 16:15:00 提供 Nasdaq GlobeNewswire

NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

03 11 2022 09:15:00 提供 Nasdaq GlobeNewswire

NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

27 10 2022 16:05:00 提供 Nasdaq GlobeNewswire

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

05 10 2022 08:15:00 提供 Nasdaq GlobeNewswire

NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

04 10 2022 16:05:00 提供 Nasdaq GlobeNewswire

NextCure to Present at the Ladenburg Thalmann Healthcare Conference

22 9 2022 08:00:01 提供 Nasdaq GlobeNewswire